Search Structure Search
wx_img
Inquiry Form
  1. Home
  2. ABBV-CLS-484

ABBV-CLS-484

Nature publishes discovery and preclinical results for ABBV-CLS-484, a potential first-in-class PTPN2/N1 inhibitor in cancer immunotherapy.
ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.

Glycine tert-Butyl Este
Glycine tert-Butyl Este
CM119469
6456-74-2
2-Methoxyethoxymethyl chloride
2-Methoxyethoxymethyl chloride
CM342464
3970-21-6
8-Fluoro-3,4-dihydro-1H-spiro[naphthalene-2,2'-[1,3]dioxolan]-6-ol
8-Fluoro-3,4-dihydro-1H-spiro[naphthalene-2,2
CM1046486
2489407-88-5
6-bromo-8-fluoro-tetralin-2-one
6-bromo-8-fluoro-tetralin-2-one
CM1018178
1337857-08-5
2-(4-bromo-2-fluorophenyl)acetyl chloride
2-(4-bromo-2-fluorophenyl)acetyl chloride
CM775631
177847-10-8
2-(4-Bromo-2-fluorophenyl)acetic acid
2-(4-Bromo-2-fluorophenyl)acetic acid
CM247871
114897-92-6